NEW YORK--(BUSINESS WIRE)--
Levi & Korsinsky announces it has commenced an investigation of Dynavax Technologies Corporation (“Dynavax” or the “Company”) (NASDAQ: DVAX) concerning possible violations of federal securities laws by certain officers and directors.
On November 14, 2016, Dynavax fell more than 62% on intraday trading following an announcement that the Company had received a Complete Response Letter from the U.S. Food and Drug Administration. According to Dynavax, the CRL requests further information on several topics “including clarification regarding specific adverse events of special interest (AESIs), a numerical imbalance in a small number of cardiac events in a single study (HBV-23), new analyses of the integrated safety data base across different time periods, and post-marketing commitments.” To obtain additional information about the investigation, go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161114006126/en/
